scholarly article | Q13442814 |
P819 | ADS bibcode | 2018NatCo...9.2363M |
P6179 | Dimensions Publication ID | 1104575301 |
P356 | DOI | 10.1038/S41467-018-04758-9 |
P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/s41467-018-04758-9 |
P932 | PMC publication ID | 6006336 |
P698 | PubMed publication ID | 29915222 |
P50 | author | Barton Haynes | Q4865631 |
Sampa Santra | Q88772993 | ||
Bhavna Hora | Q114512865 | ||
Amy M Princiotto | Q125314596 | ||
Andrés Finzi | Q60727346 | ||
Joseph Sodroski | Q64524473 | ||
P2093 | author name string | M Anthony Moody | |
Navid Madani | |||
Jonathan Richard | |||
Shilei Ding | |||
Laura Sutherland | |||
Todd Bradley | |||
Bruno Melillo | |||
Amos B Smith Iii | |||
Brandon P Conn | |||
Connie A Zhao | |||
Jérémie Prevost | |||
Linh Mach | |||
P2860 | cites work | The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens | Q22242262 |
A humanized antibody that binds to the interleukin 2 receptor | Q24600912 | ||
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 | Q24645530 | ||
Statistics review 12: survival analysis | Q24800418 | ||
Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
The neighbor-joining method: a new method for reconstructing phylogenetic trees | Q25939010 | ||
HIV-Host Interactions: Implications for Vaccine Design | Q26765966 | ||
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus | Q27644501 | ||
Molecular architecture of native HIV-1 gp120 trimers | Q27651385 | ||
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin | Q27671619 | ||
Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding | Q27675486 | ||
Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding Site | Q27681568 | ||
A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences | Q27860580 | ||
Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega | Q27860809 | ||
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding | Q28646883 | ||
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
Deciphering key features in protein structures with the new ENDscript server | Q29617219 | ||
Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates | Q30831495 | ||
B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. | Q33373664 | ||
Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. | Q44044488 | ||
Developing an HIV vaccine | Q47852386 | ||
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group | Q47887130 | ||
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. | Q53851964 | ||
Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line | Q55245697 | ||
Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs | Q59059475 | ||
Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. | Q33674461 | ||
CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies | Q33743734 | ||
Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. | Q33887674 | ||
Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds | Q33964006 | ||
Evaluation of survival data and two new rank order statistics arising in its consideration | Q34054360 | ||
Comparing individual means in the analysis of variance | Q34586410 | ||
Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing | Q34742873 | ||
Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes | Q34791232 | ||
Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions | Q35006601 | ||
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection | Q35076717 | ||
CD4 mimetics sensitize HIV-1-infected cells to ADCC. | Q35644696 | ||
CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. | Q35868046 | ||
Envelope Glycoprotein Internalization Protects Human and Simian Immunodeficiency Virus-Infected Cells from Antibody-Dependent Cell-Mediated Cytotoxicity | Q36086204 | ||
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding | Q36230268 | ||
HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans | Q36252656 | ||
Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones | Q36351700 | ||
Antigenic conservation and immunogenicity of the HIV coreceptor binding site | Q36403587 | ||
Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition | Q36681727 | ||
Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. | Q36824891 | ||
Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds | Q36878885 | ||
Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. | Q37002237 | ||
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection | Q37033294 | ||
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection | Q37273158 | ||
Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins | Q37363561 | ||
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination | Q37471315 | ||
Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds | Q37593189 | ||
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity | Q37644079 | ||
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo | Q38652858 | ||
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. | Q38713380 | ||
Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. | Q39457063 | ||
Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex | Q39878965 | ||
BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity | Q40279352 | ||
Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts | Q42670216 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2363 | |
P577 | publication date | 2018-06-18 | |
P1433 | published in | Nature Communications | Q573880 |
P1476 | title | A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. | |
P478 | volume | 9 |
Q90286963 | A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity |
Q93105022 | CD4 Incorporation into HIV-1 Viral Particles Exposes Envelope Epitopes Recognized by CD4-Induced Antibodies |
Q90262190 | Highlights from the 22nd International AIDS Conference (AIDS 2018), 22-27 July 2018, Amsterdam, the Netherlands |
Q64231610 | Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10-12 October 2018, Bethesda, MD, USA |
Q90287106 | Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV |
Q90412734 | Optimization of Small Molecules That Sensitize HIV-1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity |
Q92327047 | Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1 |
Q92482128 | Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer |
Q93079833 | Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells |
Search more.